Medicament coated refractive anterior chamber ocular implant
First Claim
1. A method of preparing a minus power anterior chamber ocular implant for placement in the anterior chamber of an eye having an anatomic lens, said method comprising:
- (a) preparing an uncoated implant which comprises (i) a negative artificial refracting lens having at least one concave surface and (ii) means for positioning the artificial lens in the anterior chamber of the eye to prevent contact between the implant and the anatomic lens;
(b) exposing the uncoated implant to a plasma to generate a plasma-treated implant having an amine-containing surface comprising primary amines; and
(c) bonding heparin to the amine-containing surface by contacting the amine-containing surface with heparin containing a terminal aldehyde group, coupling the aldehyde group to the primary amines to produce a Schiff base, and thereafter reducing the Schiff base to produce a secondary amine linkage between the heparin and implant surface, wherein bonding heparin to the amine-containing surface occurs by an end-group attachment of heparin.
5 Assignments
0 Petitions
Accused Products
Abstract
A minus power anterior chamber ocular implant for placement in the anterior chamber of a phakic eye having an anatomic lens in situ comprises a negative artificial refracting lens having at least one concave surface, a surface coating which comprises a compatible sulfated polysaccharide medicament coating, such as heparin, and and having a structure which positions having a structure which positions the artificial lens in the anterior chamber of the eye to prevent contact between the implant and the anatomic lens. The implant compensates for refractive errors or creates a specific refraction to assist in visual function and has increased biocompatibility in the anterior chamber of the eye, thereby preventing or mitigating detrimental effects typically associated with the implantation of an uncoated refractive anterior chamber implant in the eye. A method of preparing such a minus power anterior chamber ocular implant comprises first exposing an uncoated implant to a plasma to generate a plasma-treated implant having a surface containing amines, carboxylic acids, active free radicals or passive free radicals, and thereafter bonding the medicament to the plasma-treated implant surface. A method of treating myopia comprises surgically implanting and anchoring the implant in the phakic eye to compensate for refractive errors.
151 Citations
4 Claims
-
1. A method of preparing a minus power anterior chamber ocular implant for placement in the anterior chamber of an eye having an anatomic lens, said method comprising:
-
(a) preparing an uncoated implant which comprises (i) a negative artificial refracting lens having at least one concave surface and (ii) means for positioning the artificial lens in the anterior chamber of the eye to prevent contact between the implant and the anatomic lens; (b) exposing the uncoated implant to a plasma to generate a plasma-treated implant having an amine-containing surface comprising primary amines; and (c) bonding heparin to the amine-containing surface by contacting the amine-containing surface with heparin containing a terminal aldehyde group, coupling the aldehyde group to the primary amines to produce a Schiff base, and thereafter reducing the Schiff base to produce a secondary amine linkage between the heparin and implant surface, wherein bonding heparin to the amine-containing surface occurs by an end-group attachment of heparin.
-
-
2. A method of preparing a minus power anterior chamber ocular implant for placement in the anterior chamber of an eye having an anatomic lens, said method comprising:
-
(a) preparing an uncoated implant which comprises (i) a negative artificial refracting lens having at least one concave surface and (ii) means for positioning the artificial lens in the anterior chamber of the eye to prevent contact between the implant and the anatomic lens; (b) exposing the uncoated implant to a plasma to generate a plasma-treated implant having a carboxylic acid-containing surface; and (c) bonding heparin to the carboxylic acid-containing surface by first coupling an aldehyde-terminated heparin with a diamine to generate an aminated heparin, and thereafter contacting the aminated heparin with the carboxylic acid-containing surface in the presence of water-soluble carbodiimide coupling agent, wherein bonding heparin to the amine-containing surface occurs by an end-group attachment of heparin.
-
-
3. A method of preparing a minus power anterior chamber ocular implant for placement in the anterior chamber of an eye having an anatomic lens, said method comprising:
-
(a) preparing an uncoated implant which comprises (i) a negative artificial refracting lens having at least one concave surface and (ii) means for positioning the artificial lens in the anterior chamber of the eye to prevent contact between the implant and the anatomic lens; (b) exposing the uncoated implant to a plasma to generate a plasma-treated implant having an active free radical-containing surface; and (c) bonding heparin to the free radical-containing surface by first reacting at least one compound selected from the group consisting of amine and carboxylic acid-containing compounds with the free radical-containing surface, and thereafter contacting the surface with at least one heparin compound selected from the group consisting of aldehyde-terminated and aminated heparin compounds, wherein bonding heparin to the amine-containing surface occurs by an end-group attachment of heparin.
-
-
4. A method of preparing a minus power anterior chamber ocular implant for placement in the anterior chamber of an eye having an anatomic lens, said method comprising:
-
(a) preparing an uncoated implant which comprises (i) a negative artificial refracting lens having at least one concave surface and (ii) means for positioning the artificial lens in the anterior chamber of the eye to prevent contact between the implant and the anatomic lens; (b) exposing the uncoated implant to a plasma to generate a plasma-treated implant having a passive free radical-containing surface; and (c) bonding heparin to the free radical-containing surface by first reacting at least one compound selected from the group consisting of amine and carboxylic acid-containing compounds with the free radical-containing surface, and thereafter contacting the surface with at least one heparin compound selected from the group consisting of aldehyde-terminated and aminated heparin compounds, wherein bonding heparin to the amine-containing surface occurs by an end-group attachment of heparin.
-
Specification